Erasca, Inc. (ERAS)
NASDAQ · Manufacturing · Pharmaceutical preparations
$14.25−$0.2700 (−1.86%) on the dayAs of the close; data may be delayed.
ERAS price, last 12 months
Key stats
- Previous close
- $14.52
- Open
- $14.62
- Day range
- $14.23 – $14.89
- 52-week range
- $1.78 – $24.28
- Volume
- 3.2M
- Avg volume (20 days)
- 4.8M
- Market cap
- $5.0B
Performance
1W−3.5%
1M−25.6%
3M−11.0%
6M−6.0%
YTD+283.1%
1Y+646.1%
vs S&P 500, 1Y+629.3 pts
Technicals and fundamentals
About Erasca, Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $5.0B